122 related articles for article (PubMed ID: 38341288)
1. The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
Grima AA; Kwong JC; Richard L; Reid J; Raphael J; Basta NE; Carignan A; Top KA; Brousseau N; Blanchette PS; Sundaram ME;
Vaccine; 2024 Mar; 42(7):1498-1505. PubMed ID: 38341288
[TBL] [Abstract][Full Text] [Related]
2. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.
Wijn DH; Groeneveld GH; Vollaard AM; Muller M; Wallinga J; Gelderblom H; Smit EF
Eur J Cancer; 2018 Nov; 104():182-187. PubMed ID: 30368069
[TBL] [Abstract][Full Text] [Related]
3. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
5. Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Chong CR; Park VJ; Cohen B; Postow MA; Wolchok JD; Kamboj M
Clin Infect Dis; 2020 Jan; 70(2):193-199. PubMed ID: 30874791
[TBL] [Abstract][Full Text] [Related]
6. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors.
Gilbert D; Hu J; Medina T; Kessler ER; Lam ET
Hum Vaccin Immunother; 2023 Dec; 19(1):2207438. PubMed ID: 37157982
[TBL] [Abstract][Full Text] [Related]
7. Influenza Vaccination in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Tsiakos K; Kyriakoulis KG; Kollias A; Kyriakoulis IG; Poulakou G; Syrigos K
J Immunother; 2022 Jul-Aug 01; 45(6):291-298. PubMed ID: 35639000
[TBL] [Abstract][Full Text] [Related]
8. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of influenza vaccine in patients with lung cancer receiving immune checkpoint inhibitors: A single-center prospective cohort study.
Nakashima K; Homma Y; Taniguchi J; Kubota N; Otsuki A; Ito H; Otsuka Y; Kondo K; Ohfuji S; Fukushima W; Hirota Y
J Infect Chemother; 2023 Nov; 29(11):1038-1045. PubMed ID: 37481070
[TBL] [Abstract][Full Text] [Related]
10. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
Torasawa M; Yoshida T; Takeyasu Y; Shimoda Y; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
Cancer Med; 2023 Jun; 12(11):12388-12401. PubMed ID: 37062059
[TBL] [Abstract][Full Text] [Related]
11. Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors.
Gwynn ME; DeRemer DL; Saunders KM; Parikh J; Bollag RJ; Clemmons AB
J Oncol Pharm Pract; 2020 Apr; 26(3):647-654. PubMed ID: 31474214
[TBL] [Abstract][Full Text] [Related]
12. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2).
Bersanelli M; Giannarelli D; De Giorgi U; Pignata S; Di Maio M; Clemente A; Verzoni E; Giusti R; Di Napoli M; Aprile G; Ermacora P; Catino A; Scotti V; Mazzoni F; Guglielmini PF; Veccia A; Maruzzo M; Rossi E; Grossi F; Casadei C; Ficorella C; Montesarchio V; Verderame F; Rizzo M; Guaitoli G; Fratino L; Accettura C; Mencoboni M; Zustovich F; Baldessari C; Cinieri S; Camerini A; Laera L; Sorarù M; Zucali PA; Guadalupi V; Leonardi F; Tiseo M; Tognetto M; Di Costanzo F; Pinto C; Negrini G; Russo A; Migliorino MR; Filetti M; Buti S;
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016723
[TBL] [Abstract][Full Text] [Related]
13. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
Awadalla M; Golden DLA; Mahmood SS; Alvi RM; Mercaldo ND; Hassan MZO; Banerji D; Rokicki A; Mulligan C; Murphy SPT; Jones-O'Connor M; Cohen JV; Heinzerling LM; Armanious M; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Rizvi MA; Sahni G; Lyon AR; Tocchetti CG; Mercurio V; Thuny F; Ederhy S; Mahmoudi M; Lawrence DP; Groarke JD; Nohria A; Fradley MG; Reynolds KL; Neilan TG
J Immunother Cancer; 2019 Feb; 7(1):53. PubMed ID: 30795818
[TBL] [Abstract][Full Text] [Related]
14. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
[TBL] [Abstract][Full Text] [Related]
16. Immune-Related Adverse Events Among COVID-19-Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade.
Widman AJ; Cohen B; Park V; McClure T; Wolchok J; Kamboj M
J Natl Compr Canc Netw; 2022 Oct; 20(10):1134-1138. PubMed ID: 36240845
[TBL] [Abstract][Full Text] [Related]
17. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
Cook S; Samuel V; Meyers DE; Stukalin I; Litt I; Sangha R; Morris DG; Heng DYC; Pabani A; Dean M; Navani V
JAMA Netw Open; 2024 Jan; 7(1):e2352302. PubMed ID: 38236598
[TBL] [Abstract][Full Text] [Related]
18. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.
Spagnolo F; Boutros A; Croce E; Cecchi F; Arecco L; Tanda E; Pronzato P; Lambertini M
Eur J Clin Invest; 2021 Jul; 51(7):e13604. PubMed ID: 34021591
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors: immune-related adverse events, healthcare utilization, and costs among commercial and Medicare Advantage patients.
Gunturu KS; Pham TT; Shambhu S; Fisch MJ; Barron JJ; Debono D
Support Care Cancer; 2022 May; 30(5):4019-4026. PubMed ID: 35064328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
